Northwest Biotherapeutics (OTCMKTS:NWBO) Shares Cross Below 200 Day Moving Average – What’s Next?

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) shares passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $0.19 and traded as low as $0.1591. Northwest Biotherapeutics shares last traded at $0.1596, with a volume of 2,391,461 shares changing hands.

Northwest Biotherapeutics Stock Performance

The stock has a market capitalization of $277.51 million, a P/E ratio of -0.01 and a beta of -0.61. The business has a fifty day simple moving average of $0.17 and a 200-day simple moving average of $0.19.

Northwest Biotherapeutics (OTCMKTS:NWBO) last announced its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($0.01) EPS for the quarter. The firm had revenue of $0.81 million for the quarter.

Institutional Investors Weigh In On Northwest Biotherapeutics

A hedge fund recently bought a new stake in Northwest Biotherapeutics stock. Compass Financial Management LLC acquired a new stake in shares of Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,215,500 shares of the biotechnology company’s stock, valued at approximately $227,000. Compass Financial Management LLC owned 0.07% of Northwest Biotherapeutics at the end of the most recent quarter. Institutional investors own 0.04% of the company’s stock.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc is a biotechnology company focused on developing personalized cancer immunotherapies. Its lead platform uses a patient’s own dendritic cells, which are immune cells collected from the patient and prepared to recognize and stimulate an immune response against tumor tissue.

The company’s principal investigational product is DCVax-L, an autologous dendritic-cell vaccine designed for patients with glioblastoma, an aggressive form of brain cancer. Northwest Biotherapeutics has also developed DCVax-Direct, an investigational treatment intended for injection directly into inoperable solid tumors.